Stifel raised the firm’s price target on OptimizeRx (OPRX) to $16 from $12.50 and keeps a Buy rating on the shares after having hosted CEO Steve Silvestro and CFO Ed Stelmakh at Stifel’s CSI Conference. Management expanded on many key themes from the Q1 earnings report, notes the analyst, who is “encouraged by many of the changes underway, including heightened focus on financial guidance/performance.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Earnings Call: Positive Growth and Strategic Shifts
- OptimizeRx price target raised to $18 from $13 at B. Riley
- OptimizeRx price target raised to $22 from $16 at Roth Capital
- OptimizeRx price target raised to $12.50 from $8 at Stifel
- OptimizeRx price target raised to $14 from $11 at Citizens JMP